Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) shares gapped down before the market opened on Thursday . The stock had previously closed at $16.92, but opened at $16.20. Telix Pharmaceuticals shares last traded at $16.04, with a volume of 2,827 shares traded.
Wall Street Analyst Weigh In
TLX has been the subject of several research analyst reports. William Blair restated an "outperform" rating on shares of Telix Pharmaceuticals in a research report on Wednesday. HC Wainwright began coverage on shares of Telix Pharmaceuticals in a research report on Thursday, July 3rd. They set a "buy" rating and a $23.00 price target for the company. Finally, Wedbush reiterated an "outperform" rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a report on Thursday, June 12th.
Read Our Latest Stock Analysis on Telix Pharmaceuticals
Telix Pharmaceuticals Price Performance
The company has a quick ratio of 2.66, a current ratio of 2.78 and a debt-to-equity ratio of 0.99. The stock's fifty day simple moving average is $16.77 and its 200 day simple moving average is $16.95.
Institutional Trading of Telix Pharmaceuticals
An institutional investor recently bought a new position in Telix Pharmaceuticals stock. Private Advisor Group LLC purchased a new position in shares of Telix Pharmaceuticals Limited (NASDAQ:TLX - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 10,140 shares of the company's stock, valued at approximately $170,000.
Telix Pharmaceuticals Company Profile
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Further Reading
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
